Tenderwize
Retour à la recherche

Open-House Biologics Discount Contract 2025-06 - Pegvisomant

Techniker Krankenkasse·Hamburg, Germany·Deadline May 30, 2027 · 277 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-06 - Pegvisomant

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

30 / 100

Facteurs de risque

No estimated contract value is provided, making it impossible to assess potential revenue.

This is not a traditional procurement but an open-house model; legal recourse is through social courts, not procurement...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until May 2027
  • Provision of Pegvisomant pharmaceutical products under discount contracts
  • Contract term up to 24 months from June 2025
Afficher le résumé complet

Open-House procedure for pharmaceutical discount contracts (Rabattverträge) for Pegvisomant under §130a Abs. 8 SGB V. Lead buyer: Techniker Krankenkasse, with HEK and hkk as non-lead buyers. Contract runs from 01.06.2025 to 31.05.2027 (max 24 months). All qualified pharmaceutical entrepreneurs can join at any time. No estimated value or award criteria specified; procedure is non-competitive.

Risques

No estimated contract value is provided, making it impossible to assess potential revenue.

This is not a traditional procurement but an open-house model; legal recourse is through social courts, not procurement...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur as defined in §4 Abs. 18 AMG for the offered medicinal product
  • Must have a valid marketing authorization for the product in Germany/EU/EEA

Administrative

  • Must submit self-declaration on authorization and reliability (Anlage 4 zum Vertrag)

Les exigences peuvent être incomplètes.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Open-House Biologics Discount Contract 2025-06 - Pegvisomant

Conclusion of drug discount contracts for the active substance Pegvisomant via an Open-House procedure. No exclusivity; all eligible pharmaceutical entrepreneurs can participate.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

May 2025 - May 2027

Catégorie

Pharmaceutical products

Date limite

Deadline May 31, 2027

Détails de la procédure

Date de publication
08 Apr 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
229307-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3